Khoo J, et al. - In 30 obese adults with non-alcoholic fatty liver disease (NAFLD), defined as liver fat fraction (LFF) > 5% on magnetic resonance imaging without other causes of hepatic steatosis, researchers compared the impacts of weight loss induced with the glucagon-like peptide-1 agonist liraglutide, with that of lifestyle modification, followed by weight maintenance after discontinuing intervention. According to findings, liraglutide was effective in obese adults with NAFLD for reducing weight, hepatic steatosis and hepatocellular apoptosis, but in contrast to lifestyle changes, benefits were not maintained after discontinuation. The continuation of the exercise learned in the structured program helped to maintain the reduction in liver fat.